Capabilities

Growth hormone license and development agreement

OPKO Health
2015

Our attorneys advised OPKO Health in a license and development agreement with Pfizer for a long-acting human growth hormone (hGH-CTP) for adults and children. The deal terms included a US$295 million upfront payment, an additional US$275 million in milestones, and royalties and a profit share.

Email Disclaimer